ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Recommendation of “Hold” from Brokerages

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have received a consensus recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $19.00.

ADMA has been the topic of several research reports. Canaccord Genuity Group dropped their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday. Zacks Research downgraded ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Mizuho dropped their target price on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday.

Insider Buying and Selling

In related news, Director Steve Elms purchased 7,000 shares of ADMA Biologics stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the transaction, the director owned 2,038,730 shares in the company, valued at $31,946,899.10. This represents a 0.34% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the transaction, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Rothschild Investment LLC boosted its position in ADMA Biologics by 373.8% during the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the period. Summit Securities Group LLC bought a new position in ADMA Biologics in the 4th quarter worth approximately $29,000. Clearstead Advisors LLC boosted its holdings in ADMA Biologics by 55.7% in the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after buying an additional 795 shares during the period. iSAM Funds UK Ltd purchased a new position in ADMA Biologics in the 3rd quarter valued at approximately $34,000. Finally, RiverPark Advisors LLC purchased a new position in ADMA Biologics in the 3rd quarter valued at approximately $35,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Company reported strong profitability, cash flow and ASCENIV momentum — Q1 adjusted net income and adjusted EBITDA grew year?over?year, cash from operations was strong, and ASCENIV revenue rose ~28% YoY, supporting margin durability. ADMA Biologics Reports Q1 Results
• Positive Sentiment: Regulatory win: expanded ASCENIV label approval from FDA should support commercial uptake and reinforces the product growth story. FDA Expanded ASCENIV Label
• Neutral Sentiment: Earnings details mixed: EPS of $0.19 met consensus (Y/Y improvement), but revenues of $114.5M missed analyst estimates, signaling near?term topline pressure even as per?unit margins remain strong. Zacks Q1 Coverage
• Neutral Sentiment: Analyst adjustments: Mizuho trimmed its price target (from $24 to $20) but retained an outperform stance, reflecting continued conviction in long?term upside despite near?term headwinds. Benzinga Note on Mizuho
• Negative Sentiment: Company cut FY?2026 revenue guidance to $530M–$560M (consensus had been ~$625M) and withdrew longer?term guidance, citing evolving U.S. plasma/IG market dynamics — the guidance cut is the primary driver of the share decline. Seeking Alpha on Guidance Cut
• Negative Sentiment: Market scrutiny and investigations: multiple law firms have launched securities?fraud probes (Pomerantz, Kehoe, Block & Leviton, Rosen, BFA), increasing legal and reputational risk and likely amplifying sell pressure. Pomerantz Investigation Kehoe Firm Notice
• Negative Sentiment: Channel scrutiny / short?seller aftermath: media and analysts flagged potential channel stuffing and competitive pressures in the IG market; these narratives likely intensified the sell?off and elevated volatility. Investing.com on Channel Scrutiny

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $8.47 on Friday. The firm has a 50 day moving average of $12.12 and a 200-day moving average of $15.47. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 12.46 and a beta of 0.83. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $22.73.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 38.94%. ADMA Biologics’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.11 EPS. On average, equities analysts forecast that ADMA Biologics will post 0.93 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.